NO20055256L - 4-(4-heterosyklylalkoksy)fenyl)-1-(heterosyklyl-karbonyl)piperidinderivater og beslektede forbindelser som histamin H3-antagonister for behandling av neurologiske sykdommer som Alzheimers - Google Patents

4-(4-heterosyklylalkoksy)fenyl)-1-(heterosyklyl-karbonyl)piperidinderivater og beslektede forbindelser som histamin H3-antagonister for behandling av neurologiske sykdommer som Alzheimers

Info

Publication number
NO20055256L
NO20055256L NO20055256A NO20055256A NO20055256L NO 20055256 L NO20055256 L NO 20055256L NO 20055256 A NO20055256 A NO 20055256A NO 20055256 A NO20055256 A NO 20055256A NO 20055256 L NO20055256 L NO 20055256L
Authority
NO
Norway
Prior art keywords
alkyl
heterocyclyl
histamine
antagonists
treatment
Prior art date
Application number
NO20055256A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055256D0 (no
Inventor
David Kenneth Dean
David Matthew Wilson
Mark James Bamford
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20055256D0 publication Critical patent/NO20055256D0/no
Publication of NO20055256L publication Critical patent/NO20055256L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20055256A 2003-04-10 2005-11-09 4-(4-heterosyklylalkoksy)fenyl)-1-(heterosyklyl-karbonyl)piperidinderivater og beslektede forbindelser som histamin H3-antagonister for behandling av neurologiske sykdommer som Alzheimers NO20055256L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308333.4A GB0308333D0 (en) 2003-04-10 2003-04-10 Novel compounds
PCT/EP2004/003985 WO2004089373A1 (en) 2003-04-10 2004-04-08 4- (4-(heterocyclylalkoxy}phenyl)-1-(heterocyclyl-carbonyl)piperidine derivatives and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer’s

Publications (2)

Publication Number Publication Date
NO20055256D0 NO20055256D0 (no) 2005-11-09
NO20055256L true NO20055256L (no) 2006-01-10

Family

ID=9956580

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055256A NO20055256L (no) 2003-04-10 2005-11-09 4-(4-heterosyklylalkoksy)fenyl)-1-(heterosyklyl-karbonyl)piperidinderivater og beslektede forbindelser som histamin H3-antagonister for behandling av neurologiske sykdommer som Alzheimers

Country Status (22)

Country Link
US (1) US20060205774A1 (https=)
EP (1) EP1610786B9 (https=)
JP (1) JP2006522771A (https=)
KR (1) KR20050111638A (https=)
CN (1) CN1805747A (https=)
AR (1) AR044006A1 (https=)
AT (1) ATE365039T1 (https=)
AU (1) AU2004228949B2 (https=)
BR (1) BRPI0409110A (https=)
CA (1) CA2521899A1 (https=)
CO (1) CO5640135A2 (https=)
DE (1) DE602004007119T2 (https=)
ES (1) ES2288681T3 (https=)
GB (1) GB0308333D0 (https=)
IS (1) IS8118A (https=)
MA (1) MA27726A1 (https=)
MX (1) MXPA05010816A (https=)
NO (1) NO20055256L (https=)
RU (1) RU2005134006A (https=)
TW (1) TW200503710A (https=)
WO (1) WO2004089373A1 (https=)
ZA (1) ZA200507795B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
CA2609388C (en) 2005-05-30 2013-08-06 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US7553964B2 (en) * 2005-06-03 2009-06-30 Abbott Laboratories Cyclobutyl amine derivatives
DE602006010870D1 (de) 2005-06-20 2010-01-14 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
EP1896453B1 (en) 2005-06-20 2009-12-02 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
GB0514812D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
JP4860700B2 (ja) 2005-09-20 2012-01-25 シェーリング コーポレイション ヒスタミンH3アンタゴニストとして有用な、1−[[1−[(2−アミノ−6−メチル−4−ピリジニル)メチル]−4−フルオロ−4−ピペリジニル]カルボニル]−4−[2−(2−ピリジニル)−3H−イミダゾ[4,5−b]ピリジン−3−イル]ピペリジン
CA2627234A1 (en) 2005-10-27 2007-05-03 Ucb Pharma, S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
TW200730498A (en) * 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
JP2009521448A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンh3アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ
MX2008008339A (es) 2005-12-21 2008-09-03 Schering Corp Derivados de anilina sustituida ùtiles como antagonistas de la histamina h3.
UA95644C2 (ru) 2006-07-25 2011-08-25 Сефалон, Инк. Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2124933B1 (en) * 2007-01-22 2012-10-17 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
MX2010013876A (es) * 2008-06-20 2011-03-04 Metabolex Inc Agonistas de arilo grpr119 y sus usos .
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
CN109674753A (zh) 2010-06-23 2019-04-26 希玛贝治疗股份有限公司 固态分散体
EP2789608A4 (en) 2011-12-08 2015-07-01 Taisho Pharmaceutical Co Ltd PHENYLPYRROLDERIVAT
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
JP6801159B2 (ja) 2015-04-21 2020-12-16 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. イミダゾイソインドール誘導体、その製造方法及びその医薬用途
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
WO2020179780A1 (ja) * 2019-03-05 2020-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 五環式複素環化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
JPH07509694A (ja) * 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体,その使用方法および遺伝子治療のための分子スイッチ
US5364791A (en) * 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
DE4407139A1 (de) * 1994-03-04 1995-09-07 Thomae Gmbh Dr K Aryl-1-azacycloalkane und deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
CA2214288C (en) * 1996-09-18 2006-07-18 Lonza Ag Process for the preparation of 1-acyl-4-arylpiperidines
EP0837065A1 (de) * 1996-10-16 1998-04-22 Ciba SC Holding AG Phenylglycidylether-HALS
US6515013B2 (en) * 2000-07-13 2003-02-04 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
BR0108088A (pt) * 2000-07-13 2004-04-06 Abbott Lab Pirrolidinas 1,3-dissubstituìdas e 1,3,3-trissubstituìdas como ligandos receptores de histamina-3 e suas aplicações terapêuticas
ATE319696T1 (de) * 2000-08-08 2006-03-15 Ortho Mcneil Pharm Inc Nicht-imidazol aryloxyalkylamine als h3 rezeptor liganden
IL157253A0 (en) * 2001-02-28 2004-02-19 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists
US20060079533A1 (en) * 2001-03-23 2006-04-13 Nieman James A Methods of treating alzheimer's disease
US7459461B2 (en) * 2001-10-19 2008-12-02 Ortho-Mcneil Pharmaceutical, Inc. Phosphonic acid compounds as inhibitors of serine proteases

Also Published As

Publication number Publication date
ES2288681T3 (es) 2008-01-16
EP1610786B9 (en) 2008-02-27
GB0308333D0 (en) 2003-05-14
AU2004228949B2 (en) 2006-11-02
NO20055256D0 (no) 2005-11-09
EP1610786A1 (en) 2006-01-04
JP2006522771A (ja) 2006-10-05
CN1805747A (zh) 2006-07-19
ZA200507795B (en) 2006-07-26
MA27726A1 (fr) 2006-01-02
EP1610786B1 (en) 2007-06-20
RU2005134006A (ru) 2006-04-10
CO5640135A2 (es) 2006-05-31
KR20050111638A (ko) 2005-11-25
ATE365039T1 (de) 2007-07-15
DE602004007119D1 (de) 2007-08-02
DE602004007119T2 (de) 2008-02-21
AU2004228949A1 (en) 2004-10-21
MXPA05010816A (es) 2005-12-05
TW200503710A (en) 2005-02-01
CA2521899A1 (en) 2004-10-21
IS8118A (is) 2005-11-08
BRPI0409110A (pt) 2006-03-28
AR044006A1 (es) 2005-08-24
US20060205774A1 (en) 2006-09-14
WO2004089373A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
NO20055256L (no) 4-(4-heterosyklylalkoksy)fenyl)-1-(heterosyklyl-karbonyl)piperidinderivater og beslektede forbindelser som histamin H3-antagonister for behandling av neurologiske sykdommer som Alzheimers
RU2416608C2 (ru) Ароматическое соединение
RU2460725C2 (ru) Новые 2-аминооксазолины в качестве лигандов taar1
RU2201927C2 (ru) Амидиновые соединения и фармацевтическая композиция, обладающая фактор ха ингибирующим действием
RU2010138577A (ru) ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3
NO20073663L (no) Tiazol-4-karboksamid-derivater som mGluR5 antagonister
JP2019533694A5 (https=)
ME02532B (me) Jedinjenja beta-laktama supstituisana amidinom, njihovo dobijanje i upotreba kao antibakterijskih sredstava
PE20071009A1 (es) Compuestos derivados de fenoxipiperidinas como antagonistas de histamina h3
JP2002535323A5 (https=)
AR070950A1 (es) Compuestos derivados de amina, composiciones farmaceuticas de ellos, compuestos inhibidores de produccion de 11-cis-retinol y metodos para tratar enfermedades y trastornos oftalmicos
EA200601266A1 (ru) Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
JP2010504930A5 (https=)
EA200970598A1 (ru) Замещенные производные гетероарилпиридопиримидона
NO20073926L (no) Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser
RU2011127232A (ru) Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
WO2009156860A3 (en) 4-(pyridin-4-yl)-1h-(1, 3, 5)triazin-2-one derivatives as gsk3-beta inhibitors for the treatment of neurodegenerative diseases
RU2005111589A (ru) Производные 1-пиридин-4-илмочевины
HRP20080175T3 (hr) Supstituirani 2-aminotetrtalini, namijenjeni preventivnom liječenju parkinsonove bolesti
JP2011512412A5 (https=)
RU2009138219A (ru) Новые бензамидные производные и способ их получения
TR200102789T2 (tr) Cns bozukluklarının tedavisi için 1-Arensülfonil-2-aril-pirolidin ve piperidin türevleri
AR017864A1 (es) Compuestos de 1-[aril o heteroaril]-4-[3-fenil, naftil o cicloalquil-metilen, carbonil o hidroximetil]-3-[fenil-propil]piperazina, que poseen actividadsobre los receptores 1a de la serotonina, composiciones farmaceuticas formuladas con dichos compuestos; compuestos intermediarios para la sintesisde
RU2008120850A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application